IDORSIA PHARMACEUTICALS US INC
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$10.9M
Doctors Paid
41,555
Transactions
114,798
2024 Total
$1.8M
Payment Breakdown by Category
Research$3.7M (34.2%)
Food & Beverage$2.5M (22.8%)
Travel$475,902 (4.4%)
Consulting$475,437 (4.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.7M | 350 | 34.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3.7M | 1,773 | 34.0% |
| Food and Beverage | $2.5M | 110,589 | 22.8% |
| Travel and Lodging | $475,902 | 1,766 | 4.4% |
| Consulting Fee | $475,437 | 162 | 4.4% |
| Space rental or facility fees (teaching hospital only) | $16,250 | 5 | 0.1% |
| Education | $6,497 | 152 | 0.1% |
| Grant | $5,000 | 1 | 0.0% |
Payments by Type
General
$7.2M
114,448 transactions
Research
$3.7M
350 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A SINGLE-CENTER, OPEN-LABEL, RANDOMIZED, CROSSOVER PHASE 1 TRIAL TO INVESTIGATE BIOEQUIVALENCE BETWEEN 5 X 10 MG TABLETS AND 2 X 25 MG TABLETS OF DARIDOREXANT IN HEALTHY MALE AND FEMALE JAPANESE PARTICIPANTS | $1.5M | 0 | 20 |
| MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, POLYSOMNOGRAPHY, DOSE-FINDING STUDY ASSESSING THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF MULTIPLE-DOSE ORAL ADMINISTRATION OF DARIDOREXANT IN PEDIATRIC SUBJECTS AGED 10 TO < 18 YEARS WITH INSOMNIA DISORDER | $819,476 | 0 | 122 |
| A Multi-center, Double-blind, Randomized, Placebo-controlled, 2-way Cross-over Post Approval Study to Investigate the Efficacy of Daridorexant in Subjects With Insomnia and Comorbid Nocturia | $446,900 | 0 | 50 |
| A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, 2-WAY CROSS-OVER POST APPROVAL STUDY TO INVESTIGATE THE EFFICACY OF DARIDOREXANT IN SUBJECTS WITH INSOMNIA AND COMORBID NOCTURIA | $355,553 | 0 | 80 |
| A PROSPECTIVE, OPEN-LABEL, SINGLE-DOSE PHASE 1 STUDY TO MEASURE DARIDOREXANT IN BREAST MILK OF HEALTHY LACTATING WOMEN | $241,560 | 0 | 8 |
| Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Polysomnography, Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Multiple-dose Oral Administration of Daridorexant in Pediatric Subjects Aged 10 to < 18 Years With Insomnia Disorder | $162,985 | 0 | 45 |
| MULTI-CENTER DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED PARALLEL-GROUP POLYSOMNOGRAPHY DOSE-FINDING STUDY ASSESSING THE EFFICACY SAFETY AND PHARMACOKINETICS OF MULTIPLE-DOSE ORAL ADMINISTRATION OF DARIDOREXANT IN PEDIATRIC SUBJECTS AGED 10 TO < 18 YEARS WITH INSOMNIA DISORDER | $148,130 | 0 | 10 |
| CLINCIAL PRACTICE GUIDELINES ON SWITCHING HYPNOTIC MEDICINES (CONSENSUS; PUBLICATION) | $50,363 | 5 | 10 |
| RETROSPECTIVE OBSERVATIONAL ANALYSIS (PUBLICATION) | $16,170 | 2 | 4 |
| A Single-center, Open-label, Randomized, Crossover Phase 1 Trial to Investigate Bioequivalence Between 5 X 10 mg Tablets and 2 X 25 mg Tablets of Daridorexant in Healthy Male and Female Japanese Participants | $8,299 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Domingo Rodriguez-Cue, M.d, M.D | Sleep Medicine | Garner, NC | $126,658 | $0 |
| Shahrokh Javaheri, Md, MD | Pulmonary Disease | Cincinnati, OH | $123,061 | $0 |
| Dr. Gregg Friedman, Md, MD | Psychiatry | Hallandale Beach, FL | $122,356 | $0 |
| Alon Avidan, Md, MD | Sleep Medicine | Los Angeles, CA | $107,275 | $0 |
| Rajkumar Dasgupta, M.d, M.D | Pulmonary Disease | Pasadena, CA | $106,418 | $0 |
| Dr. Scott Wiener, M.d, M.D | Psychiatry | Greenfield, WI | $91,872 | $0 |
| Nathaniel Watson, Md, MD | Neurology | Seattle, WA | $86,648 | $0 |
| Dr. Damon Raskin, Md, MD | Internal Medicine | Pacific Palisades, CA | $85,149 | $0 |
| Dr. Leslie Citrome, Md, Mph, MD, MPH | Psychiatry | Pomona, NY | $83,190 | $0 |
| Michael Ledet, Md, MD | Sleep Medicine | Daphne, AL | $75,470 | $0 |
| Phillip Conner, M.d, M.D | Family Medicine | Lake Charles, LA | $69,959 | $0 |
| Jeffrey Richmond | Psychiatry | Denver, CO | $69,055 | $0 |
| Dr. Richard Bogan, M.d, M.D | Pulmonary Disease | Columbia, SC | $68,258 | $0 |
| Vikas Jain, Md, MD | Sleep Medicine | Frisco, TX | $67,502 | $0 |
| Michael Saribalas | Psychiatry | Columbus, OH | $66,594 | $0 |
| Sana Johnson-Quijada, M.d, M.D | Psychiatry | Temecula, CA | $65,867 | $0 |
| Dr. Abhinav Singh, Md, MD | Sleep Medicine | Greenwood, IN | $64,929 | $0 |
| Dr. Kenneth Halliwell, M.d, M.D | Sleep Medicine | Williamsville, NY | $61,657 | $0 |
| Paul Doghramji, Md, MD | Family Medicine | Collegeville, PA | $53,784 | $0 |
| Dr. Paul Wylie, M.d, M.D | Sleep Medicine | Little Rock, AR | $51,102 | $0 |
| Victor Rosenfeld, M.d, M.D | Neurology | Savannah, GA | $48,877 | $0 |
| Dr. Jeremy Mcconnell, M.d, M.D | Family Medicine | Bradenton, FL | $47,904 | $0 |
| Vithyalakshmi Selvaraj, M.b.b.s, M.B.B.S | Psychiatry | Omaha, NE | $47,594 | $0 |
| Justin Wasserman, M.d, M.D | Physical Medicine & Rehabilitation | Bethesda, MD | $47,185 | $0 |
| Mark Gotfried, Md, MD | Internal Medicine | Phoenix, AZ | $45,872 | $0 |
Ad
Top Products
- QUVIVIQ $9.7M
- Quviviq $618,251
Associated Products (5)
- QUVIVIQ $9.7M
- Quviviq $618,251
- Tryvio $292,034
- APROCITENTAN $77,374
- CLAZOSENTAN $35,529
Payment Categories
- Food & Beverage $2.5M
- Consulting $475,437
- Travel & Lodging $475,902
- Research $3.7M
About IDORSIA PHARMACEUTICALS US INC
IDORSIA PHARMACEUTICALS US INC has made $10.9M in payments to 41,555 healthcare providers, recorded across 114,798 transactions in the CMS Open Payments database. In 2024, the company paid $1.8M. The top product by payment volume is QUVIVIQ ($9.7M).
Payments were distributed across 252 medical specialties. The top specialty by payment amount is Psychiatry ($1.6M to 2,180 doctors).
Payment categories include: Food & Beverage ($2.5M), Consulting ($475,437), Research ($3.7M), Travel & Lodging ($475,902).
IDORSIA PHARMACEUTICALS US INC is associated with 5 products in the CMS Open Payments database, including QUVIVIQ, Quviviq, and Tryvio.